Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.…
Protara Therapeutics: Q3 Earnings Snapshot
Protara Therapeutics (NASDAQ: TARA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 46 employees.
The shares were at 2.280 USD on 20 November 2026, down 46.9% over 52 weeks. Its 52-week range is 2.090 USD to 7.820 USD: the price is 70.8% below the high and 9.1% above the low.
Its market capitalisation is 140.38M USD.
Protara Therapeutics reports return on equity of -29.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 124.61M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 10 March 2027.